Prostate Adenocarcinoma (TCGA, Cell 2015)

Summary

Prostate Adenocarcinoma (TCGA, Cell 2015) is a study catalogued by cBioPortal DataHub under the cancer-type code prad. EvidenceHelix groups it with prostate studies and lists it in the TCGA (other releases) collection.

Study description

Whole exome and/or whole genome sequencing of 333 primary prostate adenocarcinoma tumor/normal pairs; raw data at the NCI (https://tcga-data.nci.nih.gov/docs/publications/prad_2015/).

Text as published in the source's study metadata.

Citation & PubMed

TCGA, Cell 2015

Linked PubMed records: PMID 26544944

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

prad_tcga_pub

Short name

Prostate (TCGA 2015)

Source cancer-type code

prad

Reference genome

not given

Source access groups

PUBLIC

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data. TCGA data are available under the Broad Institute GDAC TCGA Analysis Pipeline License; TCGA-derived records are preliminary or legacy releases.

Citations

TCGA, Cell 2015

• PubMed record 26544944 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)

  MSK-IMPACT sequencing of 424 matched tumor-normal samples from patients with metastatic castration-sensitive prostate cancer. Germline alterations are not shown here.

  ProstateMSK studiesSource code pradPubMed 1

• Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)

  Exome sequencing of 61 prostate cancer tumor/normal pairs (50 metastatic CRPCs and 11 high-grade localized prostate cancers). Generated by Arul Chinnaiyan's and Scott Tomlins' labs at the University of Michigan.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)

  Whole exome sequencing of 444 castrate resistant prostate cancer tumor/normal pairs. SU2C-PCF Dream Team: Precision Therapy for Advanced Prostate Cancer.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)

  Whole-exome sequencing of 150 metastatic prostate cancer tumor/normal pairs by the SU2C/PCF Dream Team.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)

  Whole exome sequencing of 114 metastatic tumor/normal pairs to understand genomic overlap between castration resistant adenocarcinoma (CRPC-Adeno) and neuroendocrine histologies (CRPC-NE).

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)

  Whole genome sequencing of 57 prostate tumor and matches normal tissues.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)

  Whole-exome sequencing of 112 prostate adenocarcinomas and matched normal samples. Generated by Levi Garraway's lab at the Broad Institute and Mark Rubin's lab at Cornell.

  ProstateOther published and consortium studiesSource code pradPubMed 1

• Prostate Adenocarcinoma (CPC-GENE, Nature 2017)

  Whole-genome/exome sequencing of 477 prostate samples from CPC-GENE and public data sets, including TCGA-PRAD.

  ProstateOther published and consortium studiesSource code pradPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.